In preliminary studies, we carried out IP experiments using 4 anti-Nanog Abs, i.e., Kamiya Rb pAb, CS Rb mAb, SC H-155 Rb pAb, and R&D goat pAb using ∼500 μg NE prepared from several cultured cancer cell lines including PCa (Du145), breast cancer (MCF7), colon cancer (Colo320), and melanoma (WM562) (Fig. 3A–D; Fig. S2A). Here, NANOG is linked to breast carcinoma.